COVID-19 Outbreak and IBD Patient: A Challenge

Abstract

The COVID-19 pandemic, caused by coronavirus 2 (SARS-CoV-2), has developed as a intense challenge for healthcare systems allover the world. COVID-19 can be associated with gastrointestinal (GI) inflammation as SARS-CoV-2 enters cells via its receptor the angiotensin-converting enzyme 2, which is expressed on GI cells. There was a great demand to clarify the impact of COVID-19 on patients with inflammatory bowel disease (IBD), particularly those on immunosuppressive medications.